Ascendis Pharma A/S (ASND) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ASND Stock Alerts $135.10 -2.35 (-1.71%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 8:38 AM | marketbeat.comEvoke Wealth LLC Acquires New Shares in Ascendis Pharma A/S (NASDAQ:ASND)Evoke Wealth LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 27,069 shares of the biotechnology company's stock, vaJune 1 at 3:36 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Receives $176.88 Average Price Target from AnalystsMay 31 at 8:18 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Research Coverage Started at Stifel NicolausMay 30 at 8:30 AM | globenewswire.comAscendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024May 29, 2024 | marketbeat.comTrexquant Investment LP Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)Trexquant Investment LP bought a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 9,868 shares of the biotechnology company's stock, valued at approximately $1,243,000. Other hedge fundsMay 29, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Rating of "Moderate Buy" from AnalystsAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy ratingMay 27, 2024 | marketbeat.comArtisan Partners Limited Partnership Sells 246,181 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Artisan Partners Limited Partnership cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,749,227 shares of the biotechnologyMay 25, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Position Increased by Westfield Capital Management Co. LPWestfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,030,634 shMay 23, 2024 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Lifted to "Hold" at StockNews.comMay 23, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Raised to "Hold" at StockNews.comStockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Thursday.May 22, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Up 7%Ascendis Pharma A/S (NASDAQ:ASND) Trading 7% HigherMay 18, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) is Matisse Capital's 5th Largest PositionMatisse Capital grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 31.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,635 shares of the biotechnology comMay 17, 2024 | nasdaq.comAugust 16th Options Now Available For Ascendis Pharma (ASND)May 16, 2024 | markets.businessinsider.comAnalyst Issues ‘Buy’ Rating on Ascendis Pharma, Anticipates FDA Approval for TransCon PTHMay 15, 2024 | markets.businessinsider.comPositive Outlook on Ascendis Pharma with Buy Rating Amid Expected US Approval of TransCon PTHMay 15, 2024 | finance.yahoo.comFDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three MonthsMay 15, 2024 | marketbeat.com151,587 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by First Turn Management LLCFirst Turn Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 151,587 shares of the biotechnology companMay 15, 2024 | marketbeat.comCantor Fitzgerald Reiterates Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)Cantor Fitzgerald reiterated an "overweight" rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday.May 15, 2024 | stockhouse.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon(TM) PTH for Adults with HypoparathyroidismMay 14, 2024 | finance.yahoo.comUPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapyMay 14, 2024 | finance.yahoo.comUS Equity Markets Close Higher Tuesday as Producer Prices RiseMay 14, 2024 | reuters.comFDA extends review of Ascendis Pharma's hormone disorder therapyMay 14, 2024 | globenewswire.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismMay 13, 2024 | globenewswire.comSignificant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialMay 9, 2024 | marketbeat.comTimesSquare Capital Management LLC Lowers Position in Ascendis Pharma A/S (NASDAQ:ASND)TimesSquare Capital Management LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 792,945 shares of the biotechnology company's stock aMay 9, 2024 | globenewswire.comLatest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024May 8, 2024 | seekingalpha.comAn Update On Ascendis Pharma's Path To ProfitabilityMay 6, 2024 | finance.yahoo.comAscendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call TranscriptMay 4, 2024 | finance.yahoo.comAscendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 3, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $262.00 at Wells Fargo & CompanyWells Fargo & Company increased their price objective on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an "overweight" rating in a report on Friday.May 3, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday.May 2, 2024 | investorplace.comASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024May 2, 2024 | globenewswire.comAscendis Pharma Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comAscendis Pharma (spons ADRs) earnings preview: what to expectApril 30, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Short Interest Up 7.5% in AprilAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,600,000 shares, a growth of 7.5% from the March 31st total of 3,350,000 shares. Based on an average daily volume of 348,900 shares, the short-interest ratio is currently 10.3 days.April 29, 2024 | msn.comDevelopment dedicated to bioscience, pharma moves forward in ArlingtonApril 29, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday TradingApril 26, 2024 | benzinga.comLooking Into Ascendis Pharma's Recent Short InterestApril 25, 2024 | globenewswire.comAscendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024April 25, 2024 | marketbeat.comabrdn plc Invests $17.48 Million in Ascendis Pharma A/S (NASDAQ:ASND)abrdn plc bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 138,791 shares of the biotechnology company's stock, valued at approximately $April 24, 2024 | markets.businessinsider.comUnited Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismApril 24, 2024 | markets.businessinsider.comAscendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic HypoparathyroidismApril 24, 2024 | globenewswire.comUnited Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismApril 24, 2024 | marketbeat.comAscendis Pharma A/S (ASND) Set to Announce Quarterly Earnings on ThursdayAscendis Pharma A/S (NASDAQ:ASND) will be releasing earnings on Thursday, April 25, Yahoo Finance reports.April 22, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Rating Reiterated by Morgan StanleyMorgan Stanley reissued an "equal weight" rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a report on Monday.April 16, 2024 | marketbeat.comSequoia Financial Advisors LLC Makes New $732,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND)Sequoia Financial Advisors LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,811 shares of the biotechnology company's stock, valued at approximApril 15, 2024 | marketbeat.comRaymond James Financial Services Advisors Inc. Has $1.04 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)Raymond James Financial Services Advisors Inc. trimmed its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 45.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,224 sharesApril 14, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Sees Significant Increase in Short InterestAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,350,000 shares, a growth of 13.9% from the March 15th total of 2,940,000 shares. Based on an average daily trading volume, of 375,400 shares, the days-to-cover ratio is currently 8.9 days.April 14, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Position Reduced by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC lessened its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 203,172 shares of theApril 12, 2024 | benzinga.comAscendis Pharma's Options Frenzy: What You Need to Know Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” ASND Media Mentions By Week ASND Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.910.75▲Average Medical News Sentiment ASND News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼104▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALNY News Today TEVA News Today GMAB News Today RPRX News Today BGNE News Today BMRN News Today VTRS News Today UTHR News Today RDY News Today SRPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
